Stereotactic Core Biopsy Guidelines

Indications and Patient Selection

The American Cancer Society recommends stereotactic core needle biopsy for nonpalpable, mammographically suspicious breast lesions, particularly for BI-RADS 4 or 5 lesions requiring tissue diagnosis 3
The National Comprehensive Cancer Network suggests that stereotactic core biopsy is preferred for nonpalpable microcalcifications, which are the most common presentation requiring image-guided biopsy 1, 2
The American College of Radiology recommends stereotactic core biopsy for suspicious mammographic abnormalities where ultrasound-guided biopsy cannot be performed, such as microcalcifications typically not visible on ultrasound 1, 2

The National Comprehensive Cancer Network recommends obtaining multiple cores (at least 2-3, preferably 3-5) to ensure adequate sampling, with a strength of evidence of high 3, 4
The American Cancer Society suggests that specimen radiography must be performed to confirm retrieval of microcalcifications, with a strength of evidence of high 1, 2, 6
The National Comprehensive Cancer Network recommends leaving some microcalcifications at the biopsy site when possible to allow accurate localization for definitive excision if DCIS is diagnosed, with a strength of evidence of moderate 1, 2, 6

The National Comprehensive Cancer Network reports that the sensitivity of stereotactic core biopsy ranges from 97% to 99%, with a strength of evidence of high 3
The American Cancer Society notes that when DCIS is diagnosed by stereotactic core biopsy, invasive carcinoma will be found in approximately 20% of cases at surgical excision, with a strength of evidence of high 1, 2, 6
The National Comprehensive Cancer Network recommends that atypical ductal hyperplasia (ADH) diagnosed on core biopsy requires excisional biopsy due to underestimation rates of 20-30% for concurrent malignancy, with a strength of evidence of high 3, 7

The National Comprehensive Cancer Network recommends that concordance between pathology results, imaging findings, and clinical examination must be verified, with a strength of evidence of high 3, 4
The American Cancer Society suggests that discordance requires additional tissue sampling or surgical excision, with a strength of evidence of moderate 4
The National Comprehensive Cancer Network recommends mandatory excisional biopsy after core biopsy for atypical ductal hyperplasia (ADH), lobular carcinoma in situ (LCIS), or atypical lobular hyperplasia (ALH), with a strength of evidence of high 3

The National Comprehensive Cancer Network recommends that core biopsy provides tissue samples of sufficient size to eliminate the need for follow-up biopsy to confirm malignancy, with a strength of evidence of high 3
The American Cancer Society notes that core biopsy is more accurate than fine needle aspiration (FNA) for nonpalpable breast lesions, with a strength of evidence of high 3

The National Comprehensive Cancer Network recommends never relying on ultrasound alone for evaluation of calcifications, as ultrasound usually cannot visualize microcalcifications adequately, with a strength of evidence of high 6
The American Cancer Society suggests never assuming a benign core biopsy result is definitive without confirming radiologic-pathologic concordance, with a strength of evidence of moderate 4
The National Comprehensive Cancer Network recommends never proceeding with observation alone for ADH or other high-risk lesions diagnosed on core biopsy, as excision is mandatory, with a strength of evidence of high 3, 7